-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IJRPEcUoXJKrk+dzsyR5gWUU1QduQwmph+zsJzvWIBAOIXntlRkk352HJRYGEo6u Pd9dtjB1OfNB0rOpzb6PZA== 0000950124-05-002235.txt : 20050406 0000950124-05-002235.hdr.sgml : 20050406 20050406060115 ACCESSION NUMBER: 0000950124-05-002235 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050406 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050406 DATE AS OF CHANGE: 20050406 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HELIX BIOMEDIX INC CENTRAL INDEX KEY: 0000831749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 912099117 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-20897 FILM NUMBER: 05735729 BUSINESS ADDRESS: STREET 1: 22122 20TH AVE SE CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 425 402 8400 MAIL ADDRESS: STREET 1: 22122 20TH AVE SE CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: CARTEL ACQUISITIONS INC DATE OF NAME CHANGE: 19890718 FORMER COMPANY: FORMER CONFORMED NAME: CARIBBEAN ACQUISTIONS INC DATE OF NAME CHANGE: 19880725 8-K 1 v07677e8vk.htm FORM 8-K e8vk
 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

April 6, 2005

Commission file number: 033-20897-D

HELIX BIOMEDIX, INC.

     
Delaware   91-2099117
(State or other jurisdiction of
incorporation or organization) 		  (I.R.S. Employer
Identification No.)

22122 20TH AVENUE S.E., SUITE 148, BOTHELL, WA 98021
(Address of principal executive offices)

(425) 402-8400
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended t simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

 

 

Item 7.01 FD Disclosure
The information in this Item 7.01 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any registration statement of other document pursuant to the Securities Exchange Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

On April 6, 2005, the Registrant issued a press release announcing the issuance of a patent by the U.S. Patent and Trademark Office. The full text of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

99.1 Press Release dated April 6, 2005.

 

 

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
         
  Helix BioMedix, Inc.
(Registrant)
 		  
Date: April 6, 2005  /s/ R. Stephen Beatty    
  R. Stephen Beatty   
  President and Chief Executive Officer   

 

EX-99.1 2 v07677exv99w1.htm EXHIBIT 99.1 exv99w1
 

         

EXHIBIT 99.1

Helix BioMedix Receives Key US Patent for its Bioactive Peptides

Bothell, Washington – April 6th, 2005 — Helix BioMedix (HXBM.OB), a developer of synthetic bioactive peptides, today announced the issuance of U.S. Patent No. 6,875,744 entitled “Short Bioactive Peptides.” The patent covers a vast family of bioactive peptides designed for low cost synthesis and improved bioactivity. Specifically, this patent covers the composition of matter and use for peptides of five to 22 amino acids in length that consist, in large part, of four specific amino acids. This patent significantly expands the Company’s technology platform of proprietary peptides for therapeutic and consumer product applications.

“Securing additional patent protection for our lead peptides is a significant milestone for us,” stated R. Stephen Beatty, President and CEO. “Receipt of this patent places Helix and the Company’s intellectual property at the forefront of peptide discovery and development at a time when the world is turning to peptides for their many and varied uses. As part of our ongoing strategy, we continue to aggressively pursue intellectual property rights based on novel bioactive peptides that have been designed and synthesized by our scientists and will have the ability to utilize our vast proprietary library to screen for additional uses of these bioactive molecules.”

Peptides included in this patent form the basis of preclinical programs at Helix targeted at preventing wound infections and sexually transmitted diseases. In addition, this patent extends the Company’s worldwide competitive edge in designing inexpensive peptides, a critical factor for the consumer goods market. In total, the Company now has nine issued patents in the U.S., nine issued foreign patents and four patents pending. Helix currently has research applications in such consumer markets as acne, skin care, wrinkle reduction, deodorants, and oral care. Based upon activities of peptides observed in nature, Helix has made advancements in all of these applications by exploiting the anti-infective and stimulatory properties of these short bioactive peptides.

About Helix BioMedix

Helix BioMedix, Inc. is an early-stage biotechnology company that has a portfolio of issued patents that covers six distinct classes of peptides, covering over 100,000 unique peptide sequences. The company’s mission is to become the industry leader in developing and commercializing small proteins known as bioactive peptides. The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The company is currently focused on the development of selected peptides as topical anti-infectives and in wound healing. Non-pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care, plant health, animal health and wide-spectrum biocides. More information about the company and its proprietary peptides can be found on the company’s website at www.helixbiomedix.com.

###

Contact:

Helix BioMedix, Inc.
David Kirske, 425-402-8400
dkirske@helixbiomedix.com
or
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469
alison@cameronassoc.com

 

-----END PRIVACY-ENHANCED MESSAGE-----